title: Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the GHOST-CTO registry.
abstract: OBJECTIVE
  We aimed at comparing the acute performance of bioresorbable scaffolds (BRS) and second-generation drug-eluting stents (DES) for the treatment of chronic total occlusions (CTO).
  
  
  BACKGROUND
  There is a lack of knowledge regarding the use of BRS in CTO.
  
  
  METHODS
  Key outcomes of interest were technical and procedural success. Technical success was defined as successful stent delivery and implantation, postprocedural residual diameter stenosis <30% within the treated segment, and restoration of thrombolysis in myocardial infarction (TIMI) grade 3 flow. Procedural success was defined as technical success with no in-hospital major adverse cardiac events (MACE).
  
  
  RESULTS
  Between May 2013 and May 2014, 32 patients underwent CTO percutaneous coronary intervention (PCI) with the Absorb BRS (Abbott Vascular, Santa Clara, CA) and were compared with a historical control group of 54 patients who had undergone CTO PCI with second-generation DES. Baseline characteristics were similar between the BRS and DES groups, with the exception of a larger mean reference vessel diameter in the BRS group (2.92 ± 0.34 vs 2.50 ± 0.68; P < 0.001). Technical success was less likely to be achieved in the BRS group compared with the DES group (78.1% vs 96.3%, P = 0.012). Procedural success rates were 78.1% and 94.4% in the BRS and DES group, respectively (P = 0.035).
  
  
  CONCLUSIONS
  Compared with second-generation DES for PCI of CTO lesions, BRS were associated with lower rates of technical and procedural success. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy.
authors.forename: Alessio
authors.initials: A
authors.lastname: La Manna
authors.affiliation: Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy.
authors.forename: Alberto
authors.initials: A
authors.lastname: Chisari
authors.affiliation: Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Giacchi
authors.affiliation: Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy.
authors.forename: Davide
authors.initials: D
authors.lastname: Capodanno
authors.affiliation: Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Longo
authors.affiliation: Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Di Silvestro
authors.affiliation: Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy.
authors.forename: Piera
authors.initials: P
authors.lastname: Capranzano
authors.affiliation: Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy.|Excellence through Newest Advances (ETNA) Foundation, Catania, Italy.
authors.forename: Corrado
authors.initials: C
authors.lastname: Tamburino
mesh_terms: D020341:Absorbable Implants; D000368:Aged; D002908:Chronic Disease; D017023:Coronary Angiography; D054059:Coronary Occlusion / Q000175:diagnosis / Q000601:surgery*; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000601:surgery*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D011474:Prosthesis Design; D012042:Registries; D054457:Tissue Scaffolds; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus
keywords: bioresorbable scaffolds; chronic total occlusions